NEW YORK –– Nucleus Genomics said Friday that it has raised $14 million in Series A financing, bringing its total raised so far to $32 million.
Investors included Seven Seven Six, Founders Fund, Neo, One Eight Capital, Giant Step, Common Metal, Asylum Ventures, Rose Street Capital, Balaji Srinivasan, and Amanda Bradford.
The New York-based direct-to-consumer genomics company announced that it had also acquired artificial intelligence (AI)-based wearable health app Cambrean, whose founder, David Sloane, joined Nucleus' product team.
In a company blog post, Nucleus Founder and CEO Kian Sadeghi said the new funding will help the firm launch several new products. These include genetic risk estimations of over 800 diseases to be used in family planning, personalized drug metabolism genetic analyses, and expanded AI health tools.
The company launched a $499 genetic IQ prediction test last year, which ignited concerns among experts over the controversial science of genetics-based intelligence and its roots in 20th-century genetics. In response to that criticism, Sadeghi published a tweet stating that he disagreed with those assessments and that eugenics is "antithetical" to his vision for the company.
Nucleus previously raised $14 million in "seed plus" funding in 2022. That same year, the firm acquired Impute.me, a formerly open-source software tool for calculating polygenic risk scores.